BrainStorm Trial Shows Promising Top-Line Results for Progressive Multiple Sclerosis

BrainStorm Trial Shows Promising Top-Line Results for Progressive Multiple Sclerosis

Source: 
BioSpace
snippet: 

BrainStorm Cell Therapeutics, one of the leading developers of adult stem cell therapies that mainly focuses on adult neurodegenerative diseases, recently reported that its 28-week-long Phase II clinical trial for progressive multiple sclerosis (MS) came to a close.